Systematic analysis reveals a pan-cancer SNHG family signature predicting prognosis and immunotherapy response

Haotian Zheng; Guanghui Wang; Yadong Wang; Jichang Liu; Guoyuan Ma; Jiajun Du

doi:10.1016/j.isci.2023.108055

Systematic analysis reveals a pan-cancer SNHG family signature predicting prognosis and immunotherapy response

iScience. 2023 Sep 25;26(10):108055. doi: 10.1016/j.isci.2023.108055. eCollection 2023 Oct 20.

Authors

Haotian Zheng¹, Guanghui Wang², Yadong Wang¹, Jichang Liu¹, Guoyuan Ma², Jiajun Du^{1

3}

Affiliations

¹ Institute of Oncology, Shandong Provincial Hospital, Shandong University, Jinan, China.
² Department of Thoracic Surgery, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China.
³ Department of Thoracic Surgery, Shandong Provincial Hospital, Shandong University, Jinan, China.

Abstract

Small nucleolar RNA host genes (SNHGs) are a special family of long non-coding RNAs (lncRNAs), which not only function in a way similar to other lncRNAs but also influence the intracellular level of small nucleolar RNAs to modulate cancers. However, the features of SNHGs and their role in the prognosis and immunotherapeutic response of human cancer have not been explored. We found that SNHGs were commonly deregulated and correlated with patient survival in various cancers. The critical role of DNA methylation and somatic alterations on deregulation was also identified. SNHG family score was significantly associated with survival, multiple tumor characteristics, and tumor microenvironment. SNHG-related risk score could serve as a prognostic and immunotherapeutic response biomarker based on multiple databases. This study emphasizes the potential of SNHGs as biomarkers for prognosis and immunotherapeutic response, enabling further research into the immune regulatory mechanism and therapeutic potentials of SNHGs in cancer.

Keywords: Cancer; Computational bioinformatics; Expression study; Immune response.